沃华医药(002107) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥249,252,514.10, representing a 27.24% increase year-over-year[3] - The net profit attributable to shareholders decreased by 34.29% to ¥23,039,022.71 for the same period[3] - The net profit after deducting non-recurring gains and losses was ¥22,346,330.15, down 25.51% compared to the previous year[3] - The basic earnings per share for Q3 2022 was ¥0.04, a decrease of 33.33% year-over-year[3] - The net profit for Q3 2022 was CNY 63,423,848.29, a decrease of 54.7% compared to CNY 140,071,875.08 in Q3 2021[20] - The total profit for Q3 2022 was CNY 73,543,783.99, down 53% from CNY 156,272,539.12 in the same period last year[20] - The basic and diluted earnings per share for Q3 2022 were both CNY 0.14, compared to CNY 0.24 in Q3 2021[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,106,280,996.04, a decrease of 4.72% from the end of the previous year[4] - The total assets as of September 30, 2022, were CNY 1,106,280,996.04, down from CNY 1,161,092,124.65 at the beginning of the year[17] - The total liabilities increased to CNY 273,468,562.66 from CNY 231,829,043.56, representing a rise of 17.9%[16] - The equity attributable to shareholders decreased to CNY 749,762,369.72 from CNY 820,716,496.07, a decline of 8.6%[17] Cash Flow - The cash flow from operating activities for the year-to-date was ¥122,443,327.65, down 16.07% compared to the same period last year[8] - Cash flow from operating activities for the period was CNY 145,888,137.53, an increase of 19.2% from CNY 122,443,327.65 in the previous year[22] - The company reported a cash outflow from investing activities of CNY 2,159,798.66, an improvement from CNY 17,067,912.78 in the previous year[23] - The company’s cash outflow from financing activities was CNY 159,874,496.00, a decrease from CNY 343,690,720.26 in the previous year[23] - The company's cash and cash equivalents as of September 30, 2022, were CNY 288,640,415.39, a decrease from CNY 326,843,819.45 at the beginning of the year[14] - Cash and cash equivalents at the end of Q3 2022 were CNY 286,622,251.48, compared to CNY 273,990,376.80 at the end of Q3 2021[23] Operational Metrics - The total operating revenue for the third quarter of 2022 was CNY 752,849,548.28, an increase of 5.5% compared to CNY 711,073,285.71 in the same period last year[19] - The total operating costs for the third quarter of 2022 amounted to CNY 676,541,958.15, up 19.7% from CNY 564,970,625.95 in the previous year[19] - The total operating income for Q3 2022 was CNY 74,736,005.11, down from CNY 157,662,189.67 in Q3 2021[20] - The company reported a net profit margin decrease due to rising costs, impacting overall profitability[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 45,770[10] - The largest shareholder, Beijing Zhongzheng Wanrong Investment Group Co., Ltd., held 50.27% of the shares[10] Other Financial Information - The company reported a significant increase in accounts payable by 57.68% to ¥40,310,546.45 due to increased material procurement[7] - Accounts receivable increased to CNY 111,355,562.21 from CNY 93,319,711.03 at the start of the year, reflecting a growth of 19.4%[14] - Inventory decreased to CNY 144,317,353.40 from CNY 165,911,355.62, indicating a reduction of 13.0%[15] - Research and development expenses for the third quarter were CNY 38,274,932.52, slightly down from CNY 40,069,849.45 in the previous year[19] - The company incurred a total of CNY 1,324,177.32 in non-operating expenses during Q3 2022[20] - The company did not report any net profit from subsidiaries under common control during the period[21]